



ASX Announcement

13 August 2025

Successful Placement from Share Purchase Plan Shortfall

SYDNEY Australia, 13 August 2025 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**), is pleased to announce that it has placed the remaining shortfall of \$416,611.77 from the Share Purchase Plan (“**SPP**”) to institutional and sophisticated investors (“**Shortfall Placement**”).

The Shortfall Placement was completed after receiving inbound interest from institutional and sophisticated investors following Atomo’s recent announcement of an order from Lumos Diagnostics (ASX: LDX) for Atomo’s Pascal cassettes, to support scale up of FebriDx® demand in the US market (ASX release dated 7 August 2025: Atomo secures order for Pascal worth US\$410k from Lumos).

The Company previously raised \$272,387.50 through its SPP with the allotment of 14,723,685 shares to existing shareholders, and a further 16,810,814 shares were placed to investors who participated in the July Shortfall Placement which settled on 24 July 2025, raising a final amount of \$311,000.

The Shortfall Placement was approved by shareholders at the recent Extraordinary General Meeting held on 23 June 2025. The investors who participate in this final Shortfall Placement will be issued 22,519,555 shares at an issue price of \$0.0185 per share and 22,519,555 Options with an exercise price of \$0.04, expiring 14 August 2028, on the same terms as the SPP. It is anticipated that the Shortfall securities will be allotted on Thursday, 14 August 2025.

The Shortfall Placement was advised by Joint Lead Managers Bay Financial Pty Ltd and GBA Capital Pty Ltd. The joint lead manager fees is 6% of the funds placed. The funds raised will be used to meet the general working capital requirements and funding of its ongoing business objectives.

Managing Director & CEO & Interim Chair, John Kelly, commented:

“On behalf of the Board of Atomo Diagnostics Limited I wish to thank existing and new shareholders for their participation in the Company’s fund-raising initiatives via the Placement, Share Purchase Plan and Shortfall Placement. This additional capital places the Company in a strong position to move forward with its operational activities.”

~ ENDS ~

For more information, please contact:

John Kelly

Managing Director & CEO & Interim Chair

e. john.kelly@atomodiagnostics.com

p. +61 401 922 279

This announcement was authorised by the Board.



About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, Active Syphilis, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnostics.com